Construct validation of patient global impression of severity (PGI-S) and improvement (PGI-I) questionnaires in the treatment of men with lower urinary tract symptoms secondary to benign prostatic hyperplasia

Table 2 Correlation between PGI-S and other baseline BPH Measures in all patients

PGI-S (baseline visit)	n (%)	Mean IPSS (SD)	Mean IPSS-QoL (SD)	Mean BII (SD)	Mean Qmax (SD)
Normal	18 (1.1%)	14.9 (2.9)	2.4 (0.6)	1.1 (1.4)	10.4 (2.4)
Mild	376 (22.2%)	16.8 (3.9)	3.5 (1.1)	4.0 (2.4)	10.4 (2.7)
Moderate	1039 (61.4%)	19.8 (4.7)	4.1 (1.0)	6.7 (2.5)	9.9 (2.8)
Severe	259 (15.3%)	24.2 (5.5)	5.0 (0.9)	9.1 (2.6)	9.6 (2.9)
Overall comparison p-value		<0.001	<0.001	<0.001	0.003
Pairwise comparison p-value
Normal vs. Mild		0.092	<0.001	<0.001	0.993
Normal vs. Moderate		<0.001	<0.001	<0.001	0.461
Normal vs. Severe		<0.001	<0.001	<0.001	0.273
Mild vs. Moderate		<0.001	<0.001	<0.001	0.002
Mild vs. Severe		<0.001	<0.001	<0.001	<0.001
Moderate vs. Severe		<0.001	<0.001	<0.001	0.171
Spearman’s Correlation		0.43**	0.43**	0.53**	−0.09**

PGI-S: Patient Global Impression of Severity; IPSS: International Prostate Symptom Scores; IPSS QoL: IPSS-Quality of Life (QoL), BII - Benign Prostatic Hyperplasia Impact Index; Qmax: peak urine flow rate; n: number of patients; SD: Standard Deviation. Overall and pairwise comparison p-values are from analysis of variance without adjusting for covariates. **: p<0.001.

ISSN: 1471-2490